Received Jul 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 32YB4 | IM |
administered as IM instead of Subcutaneous; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a female patient who received MMR (Priorix) (batch number 32YB4, expiry date 01-DEC-2026) for prophylaxis. On 15-JUL-2025, the patient received Priorix (intramuscular). On 15-JUL-2025, an unknown time after receiving Priorix, the patient experienced intramuscular formulation administered by other route (Verbatim: administered as IM instead of Subcutaneous). The outcome of the intramuscular formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 16-JUL-2025 Other HCP reported regarding to the immunization Priorix, the MMR vaccine. Reporter just wanted to get information in regard because, they administered as IM instead of Subcutaneous and reporter wanted to know if there was going to be any complications for the patient or anything that should the patient know about it. The patient was administered with Priorix vaccine Intramuscularly, which led to Intramuscular formulation administered by other route.